bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1 from Interobserver Agreement in Describing the Ultrasound Appearance of Adnexal Masses and in Calculating the Risk of Malignancy Using Logistic Regression Models
Authors: Sladkevicius Povilas , Valentin Lil
Published: April 2023

Figure S1. Relationship between number of days between the two examinations and inter-observer difference in maximal tumor diameter of benign and malignant tumors is shown on this scatterplot
Supplementary Table 1 from Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma
Authors: Zelba Henning , Weide Benjamin , Martens Alexander , Derhovanessian Evelyna , Bailur Jithendra Kini , Kyzirakos Christina , Pflugfelder Annette , Eigentler Thomas K. , Di Giacomo Anna Maria , Maio Michele , Aarntzen Erik H.J.G. , de Vries Jolanda , Sucker Antje , Schadendorf Dirk , Büttner Petra , Garbe Claus , Pawelec Graham
Published: April 2023

PDF file - 32K, Survival according to the anti-influenza T-cell response pattern.
Data Supplement from Sonic Hedgehog Paracrine Signaling Activates Stromal Cells to Promote Perineural Invasion in Pancreatic Cancer
Authors: Li Xuqi , Wang Zheng , Ma Qingyong , Xu Qinhong , Liu Han , Duan Wanxing , Lei Jianjun , Ma Jiguang , Wang Xiu , Lv Shifang , Han Liang , Li Wei , Guo Jian , Guo Kun , Zhang Dong , Wu Erxi , Xie Keping
Published: April 2023

Supplementary Figure 4.Inhibition of the Hh pathway in PCa cells by blocking SMO influences cellular activity.
Supplementary Figure 1 from Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma
Authors: Zelba Henning , Weide Benjamin , Martens Alexander , Derhovanessian Evelyna , Bailur Jithendra Kini , Kyzirakos Christina , Pflugfelder Annette , Eigentler Thomas K. , Di Giacomo Anna Maria , Maio Michele , Aarntzen Erik H.J.G. , de Vries Jolanda , Sucker Antje , Schadendorf Dirk , Büttner Petra , Garbe Claus , Pawelec Graham
Published: April 2023

PDF file - 174K, Detailed Gating strategy.
Data Supplement from Sonic Hedgehog Paracrine Signaling Activates Stromal Cells to Promote Perineural Invasion in Pancreatic Cancer
Authors: Li Xuqi , Wang Zheng , Ma Qingyong , Xu Qinhong , Liu Han , Duan Wanxing , Lei Jianjun , Ma Jiguang , Wang Xiu , Lv Shifang , Han Liang , Li Wei , Guo Jian , Guo Kun , Zhang Dong , Wu Erxi , Xie Keping
Published: April 2023

Supplementary Figure 6.SHH-stimulated PSCs in subcutaneous xenograft tumors in vivo, and the number of axons from the DRG in a 3D co-culture model in vitro.
Supplementary Table 3 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
Authors: Beltran Pedro J. , Calzone Frank J. , Mitchell Petia , Chung Young-Ah , Cajulis Elaina , Moody Gordon , Belmontes Brian , Li Chi-Ming , Vonderfecht Steven , Velculescu Victor E. , Yang Guorong , Qi Jingwei , Slamon Dennis J. , Konecny Gottfried E.
Published: April 2023

PDF file - 56KB, Inhibition of cell growth by ganitumab.
Supplementary Table 1 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
Authors: Beltran Pedro J. , Calzone Frank J. , Mitchell Petia , Chung Young-Ah , Cajulis Elaina , Moody Gordon , Belmontes Brian , Li Chi-Ming , Vonderfecht Steven , Velculescu Victor E. , Yang Guorong , Qi Jingwei , Slamon Dennis J. , Konecny Gottfried E.
Published: April 2023

PDF file - 55KB, Description of ovarian cancer cell lines.
Supplementa Table 2 from A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy
Authors: Saridaki Zenia , Weidhaas Joanne B. , Lenz Heinz-Josef , Laurent-Puig Pierre , Jacobs Bart , De Schutter Jef , De Roock Wendy , Salzman David W. , Zhang Wu , Yang Dongyun , Pilati Camilla , Bouché Olivier , Piessevaux Hubert , Tejpar Sabine
Published: April 2023

Biologic characteristics of the patients according to the type of treatment.
Supplementary figures S1-8 from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
Authors: Dolman M. Emmy M. , Poon Evon , Ebus Marli E. , den Hartog Ilona J.M. , van Noesel Carel J.M. , Jamin Yann , Hallsworth Albert , Robinson Simon P. , Petrie Kevin , Sparidans Rolf W. , Kok Robbert J. , Versteeg Rogier , Caron Huib N. , Chesler Louis , Molenaar Jan J.
Published: April 2023

Supplementary figures S1-8. Fig. S1. Sensitivity of neuroblastoma cells to AT7519 is partially dependent on MYCN amplification status. Fig. S2. AT7519 more potently induces PARP cleavage in MYCN-amplified neuroblastoma cells. Fig. S3. FACS plots showing the in vitro effects of AT7519 on sub-G1 induction and the fraction of cells in G1, S and G2. Fig. S4. Effects of combination therapy with AT7519 and conventionally used drugs in neuroblastoma treatment on cell viability of IMR32. Fig. S5. AT7519 causes tumour growth inhibition in MYCN-amplified neuroblastoma xenografts after dose-dependent accumulation in the tumour. Fig. S6. AT7519 inhibits the CDK2 targets p-Rb and p-NPM in AMC711T neuroblastoma xenografts. Fig. S7. AT7519 causes tumour volume reduction in Th-MYCN transgenic mice, but tumours relapse during treatment. Fig. S8. AT7519 induces cleaved caspase 3 in Th-MYCN transgenic mice.
Supplementary Figure 1 from KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
Authors: Yoon Harry H. , Tougeron David , Shi Qian , Alberts Steven R. , Mahoney Michelle R. , Nelson Garth D. , Nair Suresh G. , Thibodeau Stephen N. , Goldberg Richard M. , Sargent Daniel J. , Sinicrope Frank A.
Published: April 2023

PDF file - 108KB, Predictive value of specific KRAS mutations in patients with BRAF-wild type resected stage III colon cancer treated with adjuvant FOLFOX chemotherapy with vs without cetuximab. Unadjusted hazard ratios (HR) for disease-free survival by KRAS mutation strata are shown for patients who were randomized during the period when KRAS-mutated and -wild type tumors were eligible. HR < 1 indicates benefit from cetuximab. No estimates produced due to insufficient sample size in one subgroup.
Supplementary Figure 2 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
Authors: Di Cosimo Serena , Sathyanarayanan Sriram , Bendell Johanna C. , Cervantes Andrés , Stein Mark N. , Braña Irene , Roda Desamparados , Haines Brian B. , Zhang Theresa , Winter Christopher G. , Jha Sharda , Xu Youyuan , Frazier Jason , Klinghoffer Richard A. , Leighton-Swayze Ann , Song Yang , Ebbinghaus Scot , Baselga José
Published: April 2023

Supplementary Figure 2. Combination therapy with ridaforolimus and dalotuzumab potentiates PI3K pathway inhibition and blocks cancer cell proliferation
Data Supplement from Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen
Authors: Hussain Maha , Corn Paul G. , Michaelson M. Dror , Hammers Hans J. , Alumkal Joshi J. , Ryan Charles J. , Bruce Justine Y. , Moran Susan , Lee Shih-Yuan , Lin H. Mark , George Daniel J.
Published: April 2023

Supplemental Figure 1. Median AMS scores for each parameter assessed: (A) total; (B) psychological; (C) sexual; (D) somatic.
Data Supplement from Demethylating Drugs as Novel Analgesics for Cancer Pain
Authors: Viet Chi T. , Dang Dongmin , Ye Yi , Ono Kentaro , Campbell Ronald R. , Schmidt Brian L.
Published: April 2023

Supplementary Figure S1. Oral SCC cells were inoculated below the hind paw epidermis; cancer cells comprising the tumor mass were seen growing below, but not invading, the epidermis. Immunohistochemistry with mu-opioid receptor antibody showed that tumors transduced with Ad-OPRM1 expressed high levels of mu-opioid receptor. Control tumors (i.e., non-transduced or transduced with Ad-GFP), did not have abundant mu-opioid receptor expression. Black bar = 100microm.
Supplementary table 4 from WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy
Authors: Bosch Linda J.W. , Luo Yanxin , Lao Victoria V. , Snaebjornsson Petur , Trooskens Geert , Vlassenbroeck Ilse , Mongera Sandra , Tang Weiliang , Welcsh Piri , Herman James G. , Koopman Miriam , Nagtegaal Iris D. , Punt Cornelis J.A. , van Criekinge Wim , Meijer Gerrit A. , Monnat Raymond J. , Carvalho Beatriz , Grady William M.
Published: April 2023

Multivariate Cox regression analysis showing the relationship between different covariates,including an interaction between WRN methylation and treatment arm, and progression free survival
Supplementary table 2 from WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy
Authors: Bosch Linda J.W. , Luo Yanxin , Lao Victoria V. , Snaebjornsson Petur , Trooskens Geert , Vlassenbroeck Ilse , Mongera Sandra , Tang Weiliang , Welcsh Piri , Herman James G. , Koopman Miriam , Nagtegaal Iris D. , Punt Cornelis J.A. , van Criekinge Wim , Meijer Gerrit A. , Monnat Raymond J. , Carvalho Beatriz , Grady William M.
Published: April 2023

Clinical characteristics of patients included in the present study and of all patients that participated the original CAIRO study
Supplementary table 1 from WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy
Authors: Bosch Linda J.W. , Luo Yanxin , Lao Victoria V. , Snaebjornsson Petur , Trooskens Geert , Vlassenbroeck Ilse , Mongera Sandra , Tang Weiliang , Welcsh Piri , Herman James G. , Koopman Miriam , Nagtegaal Iris D. , Punt Cornelis J.A. , van Criekinge Wim , Meijer Gerrit A. , Monnat Raymond J. , Carvalho Beatriz , Grady William M.
Published: April 2023

Association between WRN promoter Region 1 methylation and the molecular subclass of the specified CRC cell line, CpG island hypermethylator phenotype (CIMP) and microsatellite instability (MSI).
Supplementary figure 1 from WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy
Authors: Bosch Linda J.W. , Luo Yanxin , Lao Victoria V. , Snaebjornsson Petur , Trooskens Geert , Vlassenbroeck Ilse , Mongera Sandra , Tang Weiliang , Welcsh Piri , Herman James G. , Koopman Miriam , Nagtegaal Iris D. , Punt Cornelis J.A. , van Criekinge Wim , Meijer Gerrit A. , Monnat Raymond J. , Carvalho Beatriz , Grady William M.
Published: April 2023

Correlation between WRN methylation and mRNA expression levels in 223 CRC samples contained in TCGA data
Supplementary Table 3 from Identification of Galanin and Its Receptor GalR1 as Novel Determinants of Resistance to Chemotherapy and Potential Biomarkers in Colorectal Cancer
Authors: Stevenson Leanne , Allen Wendy L. , Turkington Richard , Jithesh Puthen V. , Proutski Irina , Stewart Gail , Lenz Heinz-Josef , Van Schaeybroeck Sandra , Longley Daniel B. , Johnston Patrick G.
Published: April 2023

PDF file - 183K, Gene set enrichment analysis
Supplementary Table 2 from Identification of Galanin and Its Receptor GalR1 as Novel Determinants of Resistance to Chemotherapy and Potential Biomarkers in Colorectal Cancer
Authors: Stevenson Leanne , Allen Wendy L. , Turkington Richard , Jithesh Puthen V. , Proutski Irina , Stewart Gail , Lenz Heinz-Josef , Van Schaeybroeck Sandra , Longley Daniel B. , Johnston Patrick G.
Published: April 2023

PDF file - 80K, Pathway analysis
Supplementary Table 1 from c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met
Authors: Stabile Laura P. , He Guoqing , Lui Vivian Wai Yan , Thomas Sufi M. , Henry Cassandra , Gubish Christopher T. , Joyce Sonali , Quesnelle Kelly M. , Siegfried Jill M. , Grandis Jennifer R.
Published: April 2023

PDF file - 38K, HNSCC cell line
Supplementary Figure Legend from c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met
Authors: Stabile Laura P. , He Guoqing , Lui Vivian Wai Yan , Thomas Sufi M. , Henry Cassandra , Gubish Christopher T. , Joyce Sonali , Quesnelle Kelly M. , Siegfried Jill M. , Grandis Jennifer R.
Published: April 2023

PDF file - 75K
Supplementary Tables 1 - 4 from Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non–Hodgkin Lymphoma
Authors: Heemann Christina , Kreuz Markus , Stoller Irene , Schoof Nils , von Bonin Frederike , Ziepert Marita , Löffler Markus , Jung Wolfram , Pfreundschuh Michael , Trümper Lorenz , Kube Dieter
Published: April 2023

PDF file, 109KB, S1: Genotype and allele frequency of the analyzed IL-10, IL-4R, TNFRI and II gene variations in patients with T-NHL (n = 117); S2: 2. 3-year survival rates for OS and EFS of patients suffering from T-NHL in relation to analyzed gene variation; S3: Real time PCR Taqman� assays used to analyze IL-10, IL-4R, TNFRI and TNFRII gene variations; S4: Primer for SNaPshot Assay used to analyze IL-10 gene variations.
Supplemental Figure S1 from A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma
Authors: Saito Motonobu , Shiraishi Kouya , Matsumoto Kenji , Schetter Aaron J. , Ogata-Kawata Hiroko , Tsuchiya Naoto , Kunitoh Hideo , Nokihara Hiroshi , Watanabe Shun-ichi , Tsuta Koji , Kumamoto Kensuke , Takenoshita Seiichi , Yokota Jun , Harris Curtis C. , Kohno Takashi
Published: April 2023

Correlation of microarray data with quantitative RT-PCR data for 12-miRNAs expression in the test cohort.
Sipplemental Figure 1 from Prostate MRI: Evaluating Tumor Volume and Apparent Diffusion Coefficient as Surrogate Biomarkers for Predicting Tumor Gleason Score
Authors: Donati Olivio F. , Afaq Asim , Vargas Hebert Alberto , Mazaheri Yousef , Zheng Junting , Moskowitz Chaya S. , Hricak Hedvig , Akin Oguz
Published: April 2023

Results of receiver operating characteristic (ROC) analysis for the identification of tumors with a Gleason score {greater than or equal to} 7. A model combining mean tumor ADC value (ADCmean) and tumor volume derived from ADC maps (VolumeADC) performed only slightly better than ADCmean alone. (Note: AUC = area under ROC curve.)
Supplementary Figure Legends, Table Legend from Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer
Authors: McNeel Douglas G. , Becker Jordan T. , Eickhoff Jens C. , Johnson Laura E. , Bradley Eric , Pohlkamp Isabel , Staab Mary Jane , Liu Glenn , Wilding George , Olson Brian M.
Published: April 2023

PDF file - 26KB
Supplementary Figures S1-S5 from Clinically Relevant Molecular Subtypes in Leiomyosarcoma
Authors: Guo Xiangqian , Jo Vickie Y. , Mills Anne M. , Zhu Shirley X. , Lee Cheng-Han , Espinosa Inigo , Nucci Marisa R. , Varma Sushama , Forgó Erna , Hastie Trevor , Anderson Sharon , Ganjoo Kristen , Beck Andrew H. , West Robert B. , Fletcher Christopher D. , van de Rijn Matt
Published: April 2023

Supplementary Figures S1-S5. Fig. S1: Implication of assuming 4 subtypes of LMS; Fig. S2: Unsupervised hierarchical clustering of core LMS cases with leiomyoma, myometrium and UPS; Fig. S3: Heatmap of IHC staining results of LMOD1 on TA-201 with five other subtype I markers reported previously; Fig. S4: Correlation between reactivity for subtype-specific IHC markers (IHC, x-axis) and mRNA expression levels (TPM, y axis) for all LMS cases; Fig. S5: Correlation of three molecular subtypes based on IHC with outcome.
Data Supplement from Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH
Authors: Wu David , Emerson Ryan O. , Sherwood Anna , Loh Mignon L. , Angiolillo Anne , Howie Bryan , Vogt Jennifer , Rieder Mark , Kirsch Ilan , Carlson Christopher , Williamson David , Wood Brent L. , Robins Harlan
Published: April 2023

Supplementary Figure 4. Pre-treatment flow cytometry for 5 cases with no clonal rearrangement of IGH, either complete V-DJ or incomplete DJ rearrangements at >10%, by high-throughput sequencing. Pre-treatment immunophenotype of neoplastic B lymphoblasts (orange) in samples in which no clonal IGH rearrangements above our criteria >10% (including complete VDJ and incomplete DJ) were detected. Background, reactive B cells (blue) are also present in some cases. There is no apparent immunophenotype to predict which cases would or would not have a clonal IGH rearrangement.
Data Supplement from Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH
Authors: Wu David , Emerson Ryan O. , Sherwood Anna , Loh Mignon L. , Angiolillo Anne , Howie Bryan , Vogt Jennifer , Rieder Mark , Kirsch Ilan , Carlson Christopher , Williamson David , Wood Brent L. , Robins Harlan
Published: April 2023

Supplementary Figure 6. Pre-treatment flow cytometry with post-treatment MRD by HTS identified in a triple flow cytometry-sorted fraction of mature B cells. To determine if mpFC was missing MRD as compared to HTS, we evaluated 10 additional samples by sequencing IGH repertoire in triple flow cytometry-sorted fraction of mature B cells (defined by uniform bright CD20 expression, bright CD45, and absence of CD10), and correlated the detected IGH sequences with the paired, pre-treatment index IGH clone. 2 samples had insufficient DNA post-sorting for sequencing analysis at a sensitivity of 1 in 10,000. Of the remaining 8 patients, one case had a clonal IGH rearrangement identified in the post-treatment sample by sequencing at a level of 0.01%, matching the index clone, but no abnormal lymphoblast population detected by flow cytometry. Flow cytometry analyses of the pre-treatment (A) and post-treatment (B) samples are shown. Orange = neoplastic lymphoblast population; blue = mature, reactive B cells; grey = background hematopoietic events (grey), including predominantly maturing elytroid and myeloid forms, are also shown in first two plots for each row.
Suplemmentary Tables 1-6, Suppementary References from Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer
Authors: Candido-dos-Reis Francisco J. , Song Honglin , Goode Ellen L. , Cunningham Julie M. , Fridley Brooke L. , Larson Melissa C. , Alsop Kathryn , Dicks Ed , Harrington Patricia , Ramus Susan J. , de Fazio Anna , Mitchell Gillian , Fereday Sian , Bolton Kelly L. , Gourley Charlie , Michie Caroline , Karlan Beth , Lester Jenny , Walsh Christine , Cass Ilana , Olsson Håkan , Gore Martin , Benitez Javier J. , Garcia Maria J. , Andrulis Irene , Mulligan Anna Marie , Glendon Gord , Blanco Ignacio , Lazaro Conxi , Whittemore Alice S. , McGuire Valerie , Sieh Weiva , Montagna Marco , Alducci Elisa , Sadetzki Siegal , Chetrit Angela , Kwong Ava , Kjaer Susanne K. , Jensen Allan , Høgdall Estrid , Neuhausen Susan , Nussbaum Robert , Daly Mary , Greene Mark H. , Mai Phuong L. , Loud Jennifer T. , Moysich Kirsten , Toland Amanda E. , Lambrechts Diether , Ellis Steve , Frost Debra , Brenton James D. , Tischkowitz Marc , Easton Douglas F. , Antoniou Antonis , Chenevix-Trench Georgia , Gayther Simon A. , Bowtell David , Pharoah Paul D.P.
Published: April 2023

Supplementary Tables S1-S6, Supplementary References. Supplementary Table S1. Characteristics of included studies; S2. Complete-case analysis of ten years estimated hazard ratios (HR) for all cause death in patients with ovarian cancer. S3. Complete-case analysis of ten years estimated subhazard ratios (SHR) for ovarian cancer death in patients with ovarian cancer. S4. Ten years estimated subhazard ratios (SHR) for ovarian cancer death in patients with ovarian cancer (with multiple imputation for missing grade and stage). S5. Complete-case analysis of ten years estimated hazard ratios (HR) for all cause death in patients with high grade serous ovarian cancer. S6. Ten years estimated hazard ratios (HR) for all cause death in patients with high grade serous ovarian cancer (with multiple imputation for missing stage).
Supplementary Tables 1-5, Figures 1-3 from Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805
Authors: Haas Naomi B. , Manola Judith , Ky Bonnie , Flaherty Keith T. , Uzzo Robert G. , Kane Christopher J. , Jewett Michael , Wood Lori , Wood Christopher G. , Atkins Michael B. , Dutcher Janice J. , Wilding George , DiPaola Robert S.
Published: April 2023

Supplementary Tables 1-5, Figures 1-3. Supplemental Table 1: Events per person-year of follow-up Supplemental Table 2: Event rates among patients randomized to sorafenib or sunitinib who started at reduced vs. full dose Supplemental Table 3a. Event rates among patients who did or did not discontinue treatment due to adverse events, and among patients with ECOG PS 0 vs. 1 Supplemental Table 3b: Baseline LVEF and change in LVEF among patients who did or did not discontinue treatment due to adverse events Supplemental Table 4: Relationship among treatment duration, baseline LVEF by MUGA, and probability of an event by any definition Supplemental Table 5: Relationship among treatment duration, baseline LVEF by MUGA, and probability of an event by the definition "Per Protocol Including Other" Supplemental Figure 1: Relationship among baseline LVEF by MUGA, treatment duration, and event status, where event is defined by any of the criteria Supplemental Figure 2: Relationship among baseline LVEF by MUGA, treatment duration, and event status, where event is defined as a decline in LVEF of 16% or more to below the lower limit of normal, or a grade 3 or higher cardiac adverse event Supplemental Figure 3: Algorithm for management of study drug-induced hypertension
Supplementary Figure 2 from Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation
Authors: Hedayati Mohammad , Haffner Michael C. , Coulter Jonathan B. , Raval Raju R. , Zhang Yonggang , Zhou Haoming , Mian Omar , Knight Emma J. , Razavi Nina , Dalrymple Susan , Isaacs John T. , Santos Aileen , Hales Russell , Nelson William G. , Yegnasubramanian Srinivasan , DeWeese Theodore L.
Published: April 2023

Formation of androgen induced DSB requires AR and TOP2B.
Supplementary Figure S4 from A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
Authors: Ferrucci Arianna , Moschetta Michele , Frassanito Maria Antonia , Berardi Simona , Catacchio Ivana , Ria Roberto , Racanelli Vito , Caivano Antonella , Solimando Antonio Giovanni , Vergara Daniele , Maffia Michele , Latorre Dominga , Rizzello Antonia , Zito Alfredo , Ditonno Paolo , Maiorano Eugenio , Ribatti Domenico , Vacca Angelo
Published: April 2023

Supplementary Figure S4. mRNA expression of the angiogenesis-related cytokines (identified by an angiogenesis Western blot array) and of the proteins (identified by mass spectrometry) in SU11274-treated MMECs.
Supplemental Table 1 from Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer
Authors: Zhong Yi , Macgregor-Das Anne , Saunders Tyler , Whittle Martin C. , Makohon-Moore Alvin , Kohutek Zachary A. , Poling Justin , Herbst Brian T. , Javier Breanna M. , Cope Leslie , Leach Steven D. , Hingorani Sunil R. , Iacobuzio-Donahue Christine A.
Published: April 2023

Patterns of Metastatic Spread by Genotype
Legend of Supplementary Figure 1 from Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases
Authors: Guidetti Anna , Carlo-Stella Carmelo , Locatelli Silvia L. , Malorni Walter , Mortarini Roberta , Viviani Simonetta , Russo Domenico , Marchianò Alfonso , Sorasio Roberto , Dodero Anna , Farina Lucia , Giordano Laura , Di Nicola Massimo , Anichini Andrea , Corradini Paolo , Gianni Alessandro M.
Published: April 2023

Legend of Supplementary Figure 1
Supplementary Video 2 from Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer
Authors: Rosenthal Eben L. , Warram Jason M. , de Boer Esther , Chung Thomas K. , Korb Melissa L. , Brandwein-Gensler Margie , Strong Theresa V. , Schmalbach Cecelia E. , Morlandt Anthony B. , Agarwal Garima , Hartman Yolanda E. , Carroll William R. , Richman Joshua S. , Clemons Lisa K. , Nabell Lisle M. , Zinn Kurt R.
Published: April 2023

Intraoperative video 2
Supplementary Methods, Supplementary Figures 1-4, Supplementary Tables 1-6 from Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Authors: Telli Melinda L. , Timms Kirsten M. , Reid Julia , Hennessy Bryan , Mills Gordon B. , Jensen Kristin C. , Szallasi Zoltan , Barry William T. , Winer Eric P. , Tung Nadine M. , Isakoff Steven J. , Ryan Paula D. , Greene-Colozzi April , Gutin Alexander , Sangale Zaina , Iliev Diana , Neff Chris , Abkevich Victor , Jones Joshua T. , Lanchbury Jerry S. , Hartman Anne-Renee , Garber Judy E. , Ford James M. , Silver Daniel P. , Richardson Andrea L.
Published: April 2023

Figure S1. Summary of HRD testing in PrECOG and combined cisplatin cohorts; Figure S2. Distribution of HRD scores in PrECOG and combined cisplatin cohorts; Figure S3. Performance of HRD in predicting response in PrECOG and combined cisplatin cohorts; Figure S4. Logistic regression models to predict response in PrECOG and combined cisplatin cohorts; Table S1. Study cohorts for threshold training set; Table S2. Summary statistics of HRD scores in BRCA1/2 deficient samples by tissue in training; Table S3. Patient clinical and demographic data; Table S4. HRD score and association with therapy response in entire cohorts; Table S5. Univariate associations between clinical variables and RCB 0/1 or HR deficiency status; Table S6. Analysis of RCB 0/1 and pCR in combined PrECOG 0105 and Cisplatin Trials cohorts (logistic regression models adjusted for cohort)
Supplementary Video 1 from Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer
Authors: Rosenthal Eben L. , Warram Jason M. , de Boer Esther , Chung Thomas K. , Korb Melissa L. , Brandwein-Gensler Margie , Strong Theresa V. , Schmalbach Cecelia E. , Morlandt Anthony B. , Agarwal Garima , Hartman Yolanda E. , Carroll William R. , Richman Joshua S. , Clemons Lisa K. , Nabell Lisle M. , Zinn Kurt R.
Published: April 2023

Intraoperative video 1
Supplemental Figures 1 - 3 from Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer
Authors: Rosenthal Eben L. , Warram Jason M. , de Boer Esther , Chung Thomas K. , Korb Melissa L. , Brandwein-Gensler Margie , Strong Theresa V. , Schmalbach Cecelia E. , Morlandt Anthony B. , Agarwal Garima , Hartman Yolanda E. , Carroll William R. , Richman Joshua S. , Clemons Lisa K. , Nabell Lisle M. , Zinn Kurt R.
Published: April 2023

Supplemental Figure S1 Pharmacokinetics of cetuximab-IRDye800. Supplemental Figure S2 Fluorescent imaging of positive margin using intraoperative instrument. Supplementary Figure S3 Opportunity for tissue saving procedures.
Supplemental Data from The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent
Authors: Phan-Lai Vy , Dang Yushe , Gad Ekram , Childs Jennifer , Disis Mary L.
Published: April 2023

Supplemental Table 1. Phenotypic characterization of T-cells in expanded T-cell lines. Supplemental Figure 1. T-cell lines derived from all cytokine conditions generated IFN-gamma response to neu p98 antigen. Supplemental Figure 2. Tumor infiltrating CD8+ T-cells post Tcell infusions. Supplemental Figure 3. Polyfunctional human HER2 specific T cells can be generated from a breast cancer patients immunized with a HER2-peptide based vaccine and expanded with IL-21/IL-2.
S5: MDM2, MDM4 and TP53 gene expression in the GBM cell lines of cohort #1 as determined by RT-qPCR. from Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Authors: Verreault Maite , Schmitt Charlotte , Goldwirt Lauriane , Pelton Kristine , Haidar Samer , Levasseur Camille , Guehennec Jeremy , Knoff David , Labussière Marianne , Marie Yannick , Ligon Azra H. , Mokhtari Karima , Hoang-Xuan Khê , Sanson Marc , Alexander Brian M. , Wen Patrick Y. , Delattre Jean-Yves , Ligon Keith L. , Idbaih Ahmed
Published: April 2023

S5: MDM2, MDM4 and TP53 gene expression in the GBM cell lines of cohort #1 as determined by RT-qPCR.
S4: MDM2, MDM4, and TP53 gene statuses in the cell lines from Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Authors: Verreault Maite , Schmitt Charlotte , Goldwirt Lauriane , Pelton Kristine , Haidar Samer , Levasseur Camille , Guehennec Jeremy , Knoff David , Labussière Marianne , Marie Yannick , Ligon Azra H. , Mokhtari Karima , Hoang-Xuan Khê , Sanson Marc , Alexander Brian M. , Wen Patrick Y. , Delattre Jean-Yves , Ligon Keith L. , Idbaih Ahmed
Published: April 2023

Mt: TP53 homozygous mutation; Amp: amplified; Del: homozygous deletion, Wt: wild-type; NL: normal level.
S2: Survival of GBM patients according to MDM2 status. from Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Authors: Verreault Maite , Schmitt Charlotte , Goldwirt Lauriane , Pelton Kristine , Haidar Samer , Levasseur Camille , Guehennec Jeremy , Knoff David , Labussière Marianne , Marie Yannick , Ligon Azra H. , Mokhtari Karima , Hoang-Xuan Khê , Sanson Marc , Alexander Brian M. , Wen Patrick Y. , Delattre Jean-Yves , Ligon Keith L. , Idbaih Ahmed
Published: April 2023

MDM2 status was determined by CGH and SNP array in the tumor of 696 GBM patients.
Supplemental Table 2 from Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma
Authors: Gustafson Michael P. , Lin Yi , Bleeker Jonathan S. , Warad Deepti , Tollefson Matthew K. , Crispen Paul L. , Bulur Peggy A. , Harrington Susan M. , Laborde Rebecca R. , Gastineau Dennis A. , Leibovich Bradley C. , Cheville John C. , Kwon Eugene D. , Dietz Allan B.
Published: April 2023

Supplemental Table 2. Univariate and multivariable associations of CD14 expression with death from RCC for 375 patients with ccRCC
Supplementary Table 4 from Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression
Authors: Lopez Sandra M. , Agoulnik Alexander I. , Zhang Manqi , Peterson Leif E. , Suarez Egla , Gandarillas Gregory A. , Frolov Anna , Li Rile , Rajapakshe Kimal , Coarfa Christian , Ittmann Michael M. , Weigel Nancy L. , Agoulnik Irina U.
Published: April 2023

SIAH2 signature in LNCaP cells
Supplementary Figure 3 from Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer
Authors: Chan Alison , Prassas Ioannis , Dimitromanolakis Apostolos , Brand Randall E. , Serra Stefano , Diamandis Eleftherios P. , Blasutig Ivan M.
Published: April 2023

Supplementary Figure 3. Complementarity of CA19.9, CA125 and LAMC2 in differentiating all PDAC patients versus healthy controls. Receiver operator characteristics (ROC) curves for CA19.9, CA125+CA19.9, CA19.9+LAMC2 and CA125+CA19.9+LAMC2 multiple markers models for all patients with pancreatic ductal adenocarcinoma (PDAC) versus healthy controls in the training (A) and validation cohort (B). The area under the curve (AUC) for each marker is provided along with its associated 95% confidence intervals in brackets.
Supplementary Figure Legends from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Authors: LoRusso Patricia M. , Li Jing , Burger Angelika , Heilbrun Lance K. , Sausville Edward A. , Boerner Scott A. , Smith Daryn , Pilat Mary Jo , Zhang Jie , Tolaney Sara M. , Cleary James M. , Chen Alice P. , Rubinstein Lawrence , Boerner Julie L. , Bowditch Adam , Cai Dongpo , Bell Tracy , Wolanski Andrew , Marrero Allison M. , Zhang Yiping , Ji Jiuping , Ferry-Galow Katherine , Kinders Robert J. , Parchment Ralph E. , Shapiro Geoffrey I.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Authors: LoRusso Patricia M. , Li Jing , Burger Angelika , Heilbrun Lance K. , Sausville Edward A. , Boerner Scott A. , Smith Daryn , Pilat Mary Jo , Zhang Jie , Tolaney Sara M. , Cleary James M. , Chen Alice P. , Rubinstein Lawrence , Boerner Julie L. , Bowditch Adam , Cai Dongpo , Bell Tracy , Wolanski Andrew , Marrero Allison M. , Zhang Yiping , Ji Jiuping , Ferry-Galow Katherine , Kinders Robert J. , Parchment Ralph E. , Shapiro Geoffrey I.
Published: April 2023

Supplementary Figure S2. Dose-exposure relationships.
Supplementary Table S1 from RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer
Authors: Calvayrac Olivier , Pradines Anne , Raymond-Letron Isabelle , Rouquette Isabelle , Bousquet Emilie , Lauwers-Cances Valérie , Filleron Thomas , Cadranel Jacques , Beau-Faller Michèle , Casanova Anne , Milia Julie , Favre Gilles , Mazières Julien
Published: April 2023

Supplementary Table S1. Characteristics of patients in the three series
Appendix 1 from Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics
Authors: Xia Jing , Trock Bruce J. , Gulati Roman , Mallinger Leslie , Cooperberg Matthew R. , Carroll Peter R. , Carter H. Ballentine , Etzioni Ruth
Published: April 2023

Simulation of times to events based on Cox regression model.
Supplementary Figure S3 from RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer
Authors: Calvayrac Olivier , Pradines Anne , Raymond-Letron Isabelle , Rouquette Isabelle , Bousquet Emilie , Lauwers-Cances Valérie , Filleron Thomas , Cadranel Jacques , Beau-Faller Michèle , Casanova Anne , Milia Julie , Favre Gilles , Mazières Julien
Published: April 2023

Supplementary Figure S3. Representative image of a PAS diastase-stained lung adenoma including a positive control of a mucin-rich bronchus
Supplementary Figure S1 from RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer
Authors: Calvayrac Olivier , Pradines Anne , Raymond-Letron Isabelle , Rouquette Isabelle , Bousquet Emilie , Lauwers-Cances Valérie , Filleron Thomas , Cadranel Jacques , Beau-Faller Michèle , Casanova Anne , Milia Julie , Favre Gilles , Mazières Julien
Published: April 2023

Supplementary Figure S1. Expression of RhoB protein in BEAS 2B-transduced cells (observed by IHC and western blotting), and representative images of the different RhoB staining intensities observed in human tumors
Supplementary Figure 1 from Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
Authors: Gross Neil D. , Bauman Julie E. , Gooding William E. , Denq William , Thomas Sufi M. , Wang Lin , Chiosea Simion , Hood Brian L. , Flint Melanie S. , Sun Mai , Conrads Thomas P. , Ferris Robert L. , Johnson Jonas T. , Kim Seungwon , Argiris Athanassios , Wirth Lori , Nikiforova Marina N. , Siegfried Jill M. , Grandis Jennifer R.
Published: April 2023

PDF file - 176KB, Assessing the Adequacy of Randomization.
Supplemental Figure 1 from Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma
Authors: Janssen Ingo , Blanchet Elise M. , Adams Karen , Chen Clara C. , Millo Corina M. , Herscovitch Peter , Taieb David , Kebebew Electron , Lehnert Hendrik , Fojo Antonio T. , Pacak Karel
Published: April 2023

Supplemental Figure 1. Mc Nemar´s test cross tabulations comparing identified (positive)/non identified (negative) lesions of [68Ga]-DOTATATE to [18F]-FDG, [18F]-FDOPA, [18F]-FDA PET/CT, and CT/MRI.
Supplementary Table 3 from Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity
Authors: Chua Jia Xin , Vankemmelbeke Mireille , McIntosh Richard S. , Clarke Philip A. , Moss Robert , Parsons Tina , Spendlove Ian , Zaitoun Abid M. , Madhusudan Srinivasan , Durrant Lindy G.
Published: April 2023

Supplementary Table 3. containing FG88 glyco-epitope expression on human tumor types. Overview of tumor TMA scoring.
Table S1 from Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer
Authors: Lee Keun-Wook , Lee Sung Sook , Hwang Jun-Eul , Jang Hee-Jin , Lee Hyun-Sung , Oh Sang Cheul , Lee Sang Ho , Sohn Bo Hwa , Kim Sang Bae , Shim Jae-Jun , Jeong Woojin , Cha Minse , Cheong Jae-Ho , Cho Jae Yong , Lim Jae Yun , Park Eun Sung , Kim Sang Cheol , Kang Yoon-Koo , Noh Sung Hoon , Ajani Jaffer A. , Lee Ju-Seog
Published: April 2023

Distribution of candidate genes in biological process categories of the Gene Ontology database.
Figure S3 from Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer
Authors: Lee Keun-Wook , Lee Sung Sook , Hwang Jun-Eul , Jang Hee-Jin , Lee Hyun-Sung , Oh Sang Cheul , Lee Sang Ho , Sohn Bo Hwa , Kim Sang Bae , Shim Jae-Jun , Jeong Woojin , Cha Minse , Cheong Jae-Ho , Cho Jae Yong , Lim Jae Yun , Park Eun Sung , Kim Sang Cheol , Kang Yoon-Koo , Noh Sung Hoon , Ajani Jaffer A. , Lee Ju-Seog
Published: April 2023

YAP1 signature is independent of TNM stages.
Figure S1 from RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition
Authors: Hayashi Takuo , Desmeules Patrice , Smith Roger S. , Drilon Alexander , Somwar Romel , Ladanyi Marc
Published: April 2023

Relationship of mutations and copy number alterations to mRNA expression of NF1 and RASA1.
supplemental legend from NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma
Authors: Huang Junwei , Zhou Yi , Thomas Gregory S. , Gu Zhimin , Yang Ye , Xu Hongwei , Tricot Guido , Zhan Fenghuang
Published: April 2023

supplemental legend
Supplemental Figure S5 from RETRACTED: Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells
Authors: Yoon Changhwan , Cho Soo-Jeong , Aksoy Bülent Arman , Park Do Joong , Schultz Nikolaus , Ryeom Sandra W. , Yoon Sam S.
Published: April 2023

Expression MYPT and effect of fasudil on spheroid formation, migration, and invasion.
Supplemental Figure S3 from RETRACTED: Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells
Authors: Yoon Changhwan , Cho Soo-Jeong , Aksoy Bülent Arman , Park Do Joong , Schultz Nikolaus , Ryeom Sandra W. , Yoon Sam S.
Published: April 2023

Expression of Akt, ERK, JNK, p38, and effects of Akt inhibition on migration and invasion.
Supplemental Figure S1 from RETRACTED: Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells
Authors: Yoon Changhwan , Cho Soo-Jeong , Aksoy Bülent Arman , Park Do Joong , Schultz Nikolaus , Ryeom Sandra W. , Yoon Sam S.
Published: April 2023

Expression of self-renewal proteins, CD44, and RhoA in monolayer and spheroid cells.
Supplemental Figure Legend from Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells
Authors: Yoon Changhwan , Cho Soo-Jeong , Aksoy Bülent Arman , Park Do Joong , Schultz Nikolaus , Ryeom Sandra W. , Yoon Sam S.
Published: April 2023

Supplemental Figure Legend
Supplementary Material from Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
Authors: Zumsteg Zachary S. , Morse Natasha , Krigsfeld Gabriel , Gupta Gaorav , Higginson Daniel S. , Lee Nancy Y. , Morris Luc , Ganly Ian , Shiao Stephan L. , Powell Simon N. , Chung Christine H. , Scaltriti Maurizio , Baselga José
Published: April 2023

Supplementary Figure Legends
Supplementary Figure legends from A Novel CDC25B Promoter–Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models
Authors: Weber Helga L. , Gidekel Manuel , Werbajh Santiago , Salvatierra Edgardo , Rotondaro Cecilia , Sganga Leonardo , Haab Gabriela Acosta , Curiel David T. , Cafferata Eduardo G. , Podhajcer Osvaldo L.
Published: April 2023

Supplementary Figure legends
Supplementary Figure S3 from A Novel CDC25B Promoter–Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models
Authors: Weber Helga L. , Gidekel Manuel , Werbajh Santiago , Salvatierra Edgardo , Rotondaro Cecilia , Sganga Leonardo , Haab Gabriela Acosta , Curiel David T. , Cafferata Eduardo G. , Podhajcer Osvaldo L.
Published: April 2023

Supplementary Figure S3. Transcriptional activity of CDC25B promoter fragment in pancreatic tumor cells in combination with gemcitabine. Expression of CD46 and Desmoglein 2 receptor in SW1990 cells
Supplementary Figures Legends from Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
Authors: Alagesan Brinda , Contino Gianmarco , Guimaraes Alexander R. , Corcoran Ryan B. , Deshpande Vikram , Wojtkiewicz Gregory R. , Hezel Aram F. , Wong Kwok-Kin , Loda Massimo , Weissleder Ralph , Benes Cyril , Engelman Jeffrey A. , Bardeesy Nabeel
Published: April 2023

Supplementary Figures Legends
Supplementary Tables 1 - 2 from Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors
Authors: Jones Robin L. , Kim Edward S. , Nava-Parada Pilar , Alam Salma , Johnson Faye M. , Stephens Andrew W. , Simantov Ronit , Poondru Srinivasu , Gedrich Rich , Lippman Scott M. , Kaye Stan B. , Carden Craig P.
Published: April 2023

Supplementary Materials Table 1. Ratio of area under the curve during the time interval between consecutive dosing (AUCtau) on day 3 to AUCtau on day 1 (schedule 1 [S1]) Table 2. Ratio of area under the curve during the time interval between consecutive dosing (AUCtau) on day 5 (S2) or day 7 (S3) to AUCtau on day 1.
Supplementary Figure 1 from Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors
Authors: Jones Robin L. , Kim Edward S. , Nava-Parada Pilar , Alam Salma , Johnson Faye M. , Stephens Andrew W. , Simantov Ronit , Poondru Srinivasu , Gedrich Rich , Lippman Scott M. , Kaye Stan B. , Carden Craig P.
Published: April 2023

Supplementary Figure 1: 79 patients enrolled in study.
Supplemental Figure S2 from Overexpression of Smad7 Blocks Primary Tumor Growth and Lung Metastasis Development in Osteosarcoma
Authors: Lamora Audrey , Talbot Julie , Bougras Gwenola , Amiaud Jérôme , Leduc Marion , Chesneau Julie , Taurelle Julien , Stresing Verena , Le Deley Marie Cécile , Heymann Marie Françoise , Heymann Dominique , Redini Françoise , Verrecchia Franck
Published: April 2023

This supplementary figure demonstrates that Smad7 and SD-208 inhibit the ability of TGF-β to promote cell migration and invasion in SAOS2 cells.
Supplementary Table S1, Figures S1-2 from Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
Authors: Choueiri Toni K. , Figueroa David J. , Fay André P. , Signoretti Sabina , Liu Yuan , Gagnon Robert , Deen Keith , Carpenter Christopher , Benson Peter , Ho Thai H. , Pandite Lini , de Souza Paul , Powles Thomas , Motzer Robert J.
Published: April 2023

Supplementary Table S1, Figures S1-2. Supplementary Table S1. Comparison of treatment outcomes between the overall study population of the COMPARZ trial and the PD-L1 study population. Supplementary Figure S1. CD8+ T cells scoring system. Supplementary Figure S2. Association of overall survival (OS) with PD-L1 expression status on tumor cell membrane.
Supplementary figures S2-S6 from KEAP1 Genetic Polymorphisms Associate with Breast Cancer Risk and Survival Outcomes
Authors: Hartikainen Jaana M. , Tengström Maria , Winqvist Robert , Jukkola-Vuorinen Arja , Pylkäs Katri , Kosma Veli-Matti , Soini Ylermi , Mannermaa Arto
Published: April 2023

Supplementary figures S2-S6. Supplementary Figure S2: A diagram depicting the location of the studied SNPs and miR-200a binding site in KEAP1 gene. Supplementary Figure S3: Association of KEAP1 rs11085735 with breast cancer survival among the KBCP and OBCS breast cancer cases. Supplementary Figure S4: Association of KEAP1 rs11085735 with breast cancer survival among the ER positive cases. Supplementary Figure S5: Association of KEAP1 rs11085735 with breast cancer survival among KBCP cases with lower (<1.33) KEAP1 protein expression. Supplementary Figure S6: Association of KEAP1 protein expression with breast cancer survival in univariate Kaplan-Meier analysis.
Supplementary Table 5 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer
Authors: Wang Rui , Wang Lei , Li Yuan , Hu Haichuan , Shen Lei , Shen Xuxia , Pan Yunjian , Ye Ting , Zhang Yang , Luo Xiaoyang , Zhang Yiliang , Pan Bin , Li Bin , Li Hang , Zhang Jie , Pao William , Ji Hongbin , Sun Yihua , Chen Haiquan
Published: April 2023

PDF file - 56KB, Correlation between FGFR fusion and expression.
Supplementary Figure 3 from Clinical Application of Prognostic Gene Expression Signature in Fusion Gene–Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group
Authors: Hingorani Pooja , Missiaglia Edoardo , Shipley Janet , Anderson James R. , Triche Timothy J. , Delorenzi Mauro , Gastier-Foster Julie , Wing Michele , Hawkins Douglas S. , Skapek Stephen X.
Published: April 2023

Box-and-whisker plot of MG5 score split by specific clinic-pathological variables, including patient gender and age, tumor histology, size, location, stage and risk group. Correlations were tested by Wilcoxon or Kruskalâˆ’Wallis rank sum tests.
Supplementary Figure 2 from Clinical Application of Prognostic Gene Expression Signature in Fusion Gene–Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group
Authors: Hingorani Pooja , Missiaglia Edoardo , Shipley Janet , Anderson James R. , Triche Timothy J. , Delorenzi Mauro , Gastier-Foster Julie , Wing Michele , Hawkins Douglas S. , Skapek Stephen X.
Published: April 2023

Box-and-whisker plot of the raw endogenous genes log intensities (A), positive and negative controls (B), Invariant Endogenous Control (C), normalized endogenous genes (D) and normalized Invariant Endogenous Control (E). (F) We also compared the log raw median gene expression versus the log upper-lower quartile range gene expression after normalization. Based on the distribution, we set a threshold at 7.6 for IQR (horizontal dotted line).
Supplementary Figure 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer
Authors: Wang Rui , Wang Lei , Li Yuan , Hu Haichuan , Shen Lei , Shen Xuxia , Pan Yunjian , Ye Ting , Zhang Yang , Luo Xiaoyang , Zhang Yiliang , Pan Bin , Li Bin , Li Hang , Zhang Jie , Pao William , Ji Hongbin , Sun Yihua , Chen Haiquan
Published: April 2023

Kaplan-Meier survival curves for relapse free and overall survival according to EGFR, KRAS, BRAF, HER2, FGFR or wild-type status